Popat, S., Solomon, B. J., Stinchcombe, T., Liu, G., Lopes, G., Johnson, M. L., Nagasaka, M., Daylan, E. C., Baik, C. S., D'Olimpio, J. T., Huang, T. J., Spira, A. I., Haggstrom, D. E., Creelan, B. C., Kehrig, K., Shen, J., DeLaRosa, R., Zhu, V. W., Drilon, A. E., Shaw, A. T. (2025). Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8666